Multi-kinase-IN-4 

Multi-kinase-IN-4 (compound 5d) is multi-targeted kinase inhibitor, including VEGFR2, EGFR, HER2, and CDK2, with IC₅₀ values of 0.33, 0.22, 0.18 and 2.09 μM, respectively. Multi-kinase-IN-4 shows broad-spectrum anti-cancer activities against HepG2, MCF-7, MDA-231, and HeLa cell lines (IC₅₀ = 1.94–7.1 µM), but exhibits lower toxicity in the WI-38 cells (IC₅₀ = 40.85 µM). Multi-kinase-IN-4 induces apoptosis and arrests cell cycle at S phase in HepG2 cells. Multi-kinase-IN-4 has the potential for the research of cancer^[1].

Multi-kinase-IN-4 (compound 5d) (48 h)对 HepG2、MCF-7、MDA-231 和 HeLa 细胞株具有细胞毒性，IC₅₀分别为 7.10、2.48、1.94 和 6.38 µM，但对 WI38 细胞的细胞毒活性较低(IC₅₀ = 64.29 µM) ^[1]。
Multi-kinase-IN-4 (7.1 µM, 24 h)使 HepG2 细胞 S 期细胞数量增加 9.23%， G0-G1 期和 G2/M 期细胞数量分别下降 4.50% 和 4.73%^[1]。
Multi-kinase-IN-4 (7.1 µM, 24 h) 诱导 HepG2 细胞早期、晚期细胞凋亡和坏死细胞死亡的比例分别为7.51%、3.45% 和 3.08%^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

402.91

C₂₁H₂₀ClFN₂OS

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ali Altharawi, et al. Novel 2-Sulfanylquinazolin-4(3H)-one Derivatives as Multi-Kinase Inhibitors and Apoptosis Inducers: A Synthesis, Biological Evaluation, and Molecular Docking Study. Molecules. 2023 Jul; 28(14): 5548.